TLT Share Price

Open 0.46 Change Price %
High 0.48 1 Day 0.02 4.35
Low 0.45 1 Week 0.04 9.09
Close 0.48 1 Month 0.11 29.73
Volume 209265 1 Year 0.06 14.29
52 Week High 0.54
52 Week Low 0.17
TLT Important Levels
Resistance 2 0.51
Resistance 1 0.50
Pivot 0.47
Support 1 0.46
Support 2 0.45
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
THM 0.32 128.57%
THM 0.32 128.57%
CPV 0.04 100.00%
CPV 0.04 100.00%
BVQ 0.02 100.00%
DYG 0.02 100.00%
DDX 0.50 100.00%
VRS 0.02 100.00%
VRS 0.02 100.00%
AZU 0.02 100.00%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
ROI 0.02 -33.33%
CD 0.02 -33.33%
More..

Theralase Technologies Inc (CVE: TLT)

TLT Technical Analysis 5
As on 18th Aug 2017 TLT Share Price closed @ 0.48 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.36 & Strong Buy for SHORT-TERM with Stoploss of 0.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TLT Target for August
1st Target up-side 0.57
2nd Target up-side 0.63
3rd Target up-side 0.69
1st Target down-side 0.41
2nd Target down-side 0.35
3rd Target down-side 0.29
TLT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.theralase.com
TLT Address
TLT
1945 Queen Street East
Toronto, ON M4L 1H7
Canada
Phone: 416-699-5273
TLT Latest News
Theralase Technologies' lead compound shown to destroy lung cancer   Proactive Investors UK   - 08th Aug 17
Theralase Technologies moves to second phase in bladder cancer trial   Proactive Investors UK   - 01st Aug 17
Theralase Technologies shares rocket on TLD-1433 clinical trial findings   Proactive Investors UK   - 25th Jul 17
OTC Markets Group Welcomes Theralase Technologies Inc. to OTCQX   PR Newswire (press release)   - 02nd Jun 17
Theralase to expand bladder cancer trial after initial success   Proactive Investors USA & Canada   - 26th May 17
Theralase Technologies' anti-cancer compound passes milestone   Proactive Investors UK   - 22nd Apr 16
Theralase Technologies gets clinical trial go-ahead   Proactive Investors USA & Canada   - 17th Dec 15
Initiation Report For Theralase Technologies   Seeking Alpha   - 09th May 14
Theralase Technologies Inc: A Cure for Cancer?   Midas Letter   - 24th Feb 14
0.45   MarketWatch   - 24th Apr 11
Interactive Technical Analysis Chart Theralase Technologies Inc ( TLT CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Theralase Technologies Inc
TLT Business Profile
Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in biostimulative and biodestructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical research, clinical trials, and new technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and development activities. The company sells its products in Canada, the United States, and internationally. Theralase Technologies Inc. is headquartered in Toronto, Canada.